Research and Development

Our main research goal is to develop innovative medicines. The most important are the new pharmaceutically active substances which envelop the new principles of disease treatment.

The closest attention is paid to the innovations which are supposed to give new pharmacokinetic properties to the already known medicines.

Major effort has been put into the avenues of research which are the most significant for the company. We work on new molecules for the treatment of such diseases as tuberculosis, oncopathology, HIV.

The Pharmasyntez company in cooperation with the Irkutsk Institute of Chemistry SB RAS developed the original medicine for the treatment of multiple drug resistance tuberculosis (MDRTB) – Perchlozone^®.

This medicine is the first innovative tuberculosis treatment in the last 40 years. Perchlozone^® was registered and introduced to the market in 2012 after successful clinical testing. Nowadays the IV phase of clinical testing is conducted.

In 2012 the Pharmasyntez company in cooperation with the Irkutsk Scientific Center of Surgery and Traumatology developed medicine for postoperative adhesions prevention – Seroguard^®.

The preclinical testing and the first phase of clinical trials were successfully carried out with the assistance of the Russian Federation Ministry of Industry and Trade.

Showing a safety profile similar to placebo Seroguard^® entered the second phase of clinical trials.

Once these clinical trials are successfully completed, surgeons of various specialties will receive the medicine with unique features. It will aim to prevent postoperative complications which are almost inevitable now.